ClinicalTrials.gg
Status unknownNCT05379114Updated Jun 1, 2022

Comparative Study for the Evaluation of a New Medical Device on the Treatment of Head Lice Infestation

An interventional study of INVESTIGATIONAL DEVICE and Comparator device in Head Lice, sponsored by Perrigo CSCI. Status unknown at 1 site in Mauritius. Open to participants aged 2 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-01.

Sponsored by Perrigo CSCI · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Study summary

Pediculosis capitis or head lice infestation is a human medical condition caused by the infestation of the hair by the parasitic insect Pediculus humanus capitis (human head lice). The most common symptom of infestation is pruritus (itching) on the head which normally intensifies 3 to 4 weeks after the initial infestation.

The test item has been developed with the ambition to offer a complete head lice treatment, whilst also offering ultimate convenience in use - making treatment of head lice infestation easy, and effective in few minutes.

The objectives of this clinical study are to assess the efficacy and the safety of a new Medical Device for lice infestation treatment compared to a comparator device, already in market.

02

Conditions studied

  • Head Lice
03

In context

Lead sponsor

Perrigo CSCI is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy subject;
  2. Sex: male or female;
  3. Age: 2 years and above;
  4. Subject with a slight to moderate lice infestation
  5. Subjects with various hair type (from 1 to 3C - hair scale) and hair length (from short to mid length hair, not exceeding shoulder)
  6. Documented oral for all subjects, including minors, given freely and expressly before the start of the study
  7. Written informed consent for subjects ≥18 years or legal guardian for subjects\< 18 years given freely and expressly before start of the study;
  8. Written assent for subjects ≥12 to \<18 years.
  9. Subject/Subject's legal guardian is psychologically able to understand the study related information and to give written informed consent;
  10. Females of must have a negative pregnancy test before the beginning of the study

Exclusion criteria

Exclusion Criteria:

In terms of population

  1. Pregnant (confirmed by pregnancy test for women of ) or nursing woman or planning a pregnancy during the study;
  2. Subject who had been deprived of their freedom by administrative or legal decision or adult subject who is under guardianship;
  3. Subject in a social or sanitary establishment;
  4. Subject in an exclusion period from a previous study or who is currently participating to another study on hair/scalp or who participated to another clinical study on hair/scalp within 3 months before first visit.
  5. Subject suspected to be non-compliant according to the Investigator's judgment.
  6. Subject with curly or frizzy hair (type 4a to 4c in the hair type scale above)
  7. Subject with hair length below the shoulder.
  8. Subjects with more than 24 lice on the head

    In terms of associated pathology

  9. Subject suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the study results.
  10. Subject with a cutaneous disease on the studied zone (scalp and hair).
  11. Subject with severe scratches or open wounds/skin damages on the scalp (lice bites allowed however).
  12. Subject with a known or suspected allergy to any of the components/materials of the or comparator devices, anti-lice comb or post-treatment shampoo.
  13. Subject who has diabetes (type 1 or 2).
  14. Subject with known or suspected immune deficiency or disease.

    Relating to previous or ongoing treatment

  15. Subject undergoing a topical treatment on the test area or a systemic treatment with :

    • anti-inflammatory medication and/or anti-histamines during the previous 2 weeks and during the study;
    • during the 2 previous weeks and during the study;
    • retinoids and/or immunosuppressors during the 3 previous months and during the study;
    • any medication stabilized for less than one month.
  16. Subject who received an anti-lice treatment in the previous 2 months.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
136 participants (estimated)

Study arms

  • Experimental
    INVESTIGATIONAL DEVICE

    new medical device for the treatment of head lice infestation: Paranix ®

    Other: INVESTIGATIONAL DEVICE

  • Active comparator
    COMPARATOR DEVICE

    dimethicone based head lice treatment (medical device class 1) already in market in europe: Pouxit ®

    Other: Comparator device

Interventions

  • OtherINVESTIGATIONAL DEVICE

    new medical device for the treatment of head lice infestation: Paranix ®

  • OtherComparator device

    well established medical device for the treatment of head lice infestation (dimethicone based) - Pouxit ®

06

What researchers measure

Primary outcomes

  1. Cure Rate after complete treatment

    The cure rate is defined as the rate of subjects having no live lice on scalp 7 days after the last application of the product.

    Time frame: day 7

  2. Cure Rate after complete treatment

    The cure rate is defined as the rate of subjects having no live lice on scalp 7 days after the last application of the product.

    Time frame: day 14

Secondary outcomes

  1. Cure rate after one dose of Investigational device (ID)

    Comparison of the percentage of subjects cured after one dose of the investigational device compared to the percentage of subjects cured with two doses of the comparator device.

    Time frame: Day 7

  2. Dead and live lice/nymphs and number of eggs after combing

    Number of dead and live lice/nymphs and number of eggs collected on the anti-lice comb after treatment

    Time frame: Day 0 and Day 7 if applicable

  3. Live lice and nymphs, after application

    Evaluation of the presence of live lice and nymphs, for both groups, without combing on scalp

    Time frame: Day 1 and Day 8 if applicable

  4. Number of participants with treatment-related adverse events as assessed by investigator

    Evaluation of the safety and tolerability of the investigational device versus comparator

    Time frame: Day 0, 7, 8 and 14 if applicable

  5. Subject reported perceived acceptability, effectiveness and subjective evaluation assessed via questionnaire data

    Evaluation of the perceived acceptability, effectiveness and subjective evaluation. Subject perception questionnaire with the following scale items: totally agree agree rather agree rather disagree disagree

    Time frame: Day 7 or Day14

07

Study locations

1 of 1 sites recruiting
  • Céline Lhéritier
    Quatre Bornes, Mauritius
    Recruiting
    • Céline Lhéritier · Contactclh@dermscan.com · +33671323320
    • Aslham DOARIKA, Dr · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2022 (actual). Primary completion is estimated for Jul 2022, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2022
First posted
May 18, 2022
StartActual
May 18, 2022
Primary completionEst.
Jul 2022
CompletionEst.
Sep 2022
Last update
Jun 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05379114
Lead sponsor
Perrigo CSCI
Responsible party
Sponsor
First posted
May 18, 2022
Start date
May 18, 2022
Primary completion
Jul 2022 (estimated)
Completion
Sep 2022 (estimated)
Last update
Jun 1, 2022

Study contacts

Céline Lhéritier
Contact
clh@dermscan.com
+33 (0)6 71 32 33 20

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion